Navigation Links
Antidepressants While Pregnant Linked to Slight Risk of Lung Problem in Babies
Date:1/13/2012

By Steven Reinberg
HealthDay Reporter

THURSDAY, Jan. 12 (HealthDay News) -- Women who use antidepressants called selective serotonin-reuptake inhibitors such as Prozac and Celexa during pregnancy run a slight risk of having an infant with high blood pressure in the lungs, a new Swedish study finds.

The condition, known as persistent pulmonary hypertension, can lead to shortness of breath and difficulty breathing. Although rare, severe disease is associated with heart failure, the investigators noted.

"Infants born to women treated with SSRIs in late pregnancy had a twofold increased risk [of] their infants having persistent pulmonary hypertension," said lead researcher Dr. Helle Kieler, head of the Centre for Pharmacoepidemiology at Karolinska University Hospital in Stockholm.

"The increased risk seemed to be a class effect of SSRIs, as risks for the specific SSRIs were of similar magnitude," she added.

Women taking SSRIs should be informed about the increased risk, but they should also be told that persistent pulmonary hypertension is a rare disease that affects fewer than two of 1,000 newborns, Kieler said.

"If possible, non-medical treatment for depression during pregnancy should be considered," she said. "For women where treatment with an SSRI is the only or best option, the choice of substance is of less importance."

Dr. Gideon Koren, director of the Motherisk Program at The Hospital for Sick Children at the University of Toronto and author of an accompanying journal editorial, said this finding does not prove that SSRIs cause persistent pulmonary hypertension.

"It is important that, before we scare pregnant women not to treat their depression in pregnancy, we ensure that the science overcomes its methodological limitations," he said.

"Most notably, the authors have chosen SSRIs as the potential cause for persistent pulmonary hypertension, while their results show that untreated depression can also do it," Koren said.

Based on these data, "we cannot yet conclude that use of SSRIs causes persistent pulmonary hypertension in some babies," he said.

The report was published in the Jan. 12 online issue of the BMJ.

For the study, Kieler's team collected data on more than 1 million births from 1996 and 2007 in Denmark, Finland, Iceland, Norway and Sweden.

Among the mothers, nearly 11,000 took SSRIs during late pregnancy and about 17,000 took them during early pregnancy. Most of these women were older and smoked, researchers reported.

In addition, more than 54,000 mothers had been previously diagnosed with mental problems, but were not taking any medication.

Among the women taking SSRIs, Kieler's group looked at the use of fluoxetine (Prozac), fluvoxamine (Luvox), citalopram (Celexa), paroxetine (Paxil), sertraline (Zoloft) and escitalopram (Lexapro).

Fluvoxamine was rarely used and none of the children with persistent pulmonary hypertension were exposed to it, the researchers noted.

Of the nearly 11,000 mothers who used an SSRI in late pregnancy, 33 babies (0.2 percent) were born with persistent pulmonary hypertension, the researchers found.

Of the more than 17,000 women who used SSRIs in early pregnancy, 32 babies (less than 0.2 percent) suffered persistent pulmonary hypertension, they added.

Among the 54,000 mothers who had previously been diagnosed with a mental problem but who did not take SSRIs during their pregnancy, 114 infants were born with persistent pulmonary hypertension, Kieler's group found.

Other factors such as Cesarean delivery or low birth weight were not associated with persistent pulmonary hypertension, they noted.

Another expert, Dr. Ilene Sosenko, a professor of pediatrics and neonatology at the University of Miami School of Medicine, said this study won't change clinical practice.

"The risk of persistent pulmonary hypertension is very low and even though there is a higher risk with SSRIs, the risk remains extremely low," she said. "From a clinical standpoint, the risk is not increased to the point where it would change the pattern of the way doctors are managing their pregnant women," she said.

Managing the depression is probably more important than worrying about the risk of persistent pulmonary hypertension, Sosenko said.

"Depression can impact on how the mother eats or whether she takes other drugs or whether she gets her prenatal care," she said. "Although there is a very small increased risk of persistent pulmonary hypertension, the benefit of remaining on SSRI medication is important."

More information

For more on depression during pregnancy, visit the American Pregnancy Association.

SOURCES: Helle Kieler, M.D., Ph.D., associate professor and head, Centre for Pharmacoepidemiology, Karolinska University Hospital, Stockholm, Sweden; Gideon Koren, M.D., director, Motherisk Program, The Hospital for Sick Children, and professor, pediatrics, pharmacology, pharmacy and medical genetics, University of Toronto; Ilene Sosenko, M.D., professor, pediatrics and neonatology, University of Miami School of Medicine; Jan. 12, 2012, BMJ, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Antidepressants in Pregnancy May Delay Developmental Milestones
2. A new generation of rapid-acting antidepressants?
3. Kids Suicide Risk Same for All Antidepressants
4. Antidepressants May Ease Damage From Stroke
5. Antidepressants May Improve Heart Health
6. Antidepressants in pregnancy increase risk of miscarriage
7. Certain Popular Antidepressants Linked to Cataracts in Seniors
8. Autism: Lack of evidence for antidepressants
9. Decrease in suicide not linked to newer antidepressants
10. Antidepressants linked to thicker arteries
11. Study Hints at Link Between Antidepressants and Heart Trouble
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, and the ... results and maintaining GMP and USP compliance. In a new webinar from METTLER ... requirements " these requirements are explained. The challenge is to determine how ...
(Date:3/28/2017)... San Francisco, CA (PRWEB) , ... March 28, 2017 , ... ... million people suffering from acne, access to quality care can be limited while the ... skincare company that offers customized prescription acne care for every customer online, today released ...
(Date:3/28/2017)... ... 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics ... in the country to sit on the 2017 National Advisory Board for Allergan’s Facial ... Dr. Harper helped propel the clinic from a small start-up to number 78 in ...
(Date:3/28/2017)... ... 2017 , ... Public relations pros work hard to earn placements and ... While many results are clear, much of PR is hard to quantify. Goal-setting and ... to measurement, firms should always take an all-inclusive approach that takes both traditional and ...
(Date:3/28/2017)... ... ... Oily skin is a common and unwelcomed occurrence in people of all ages, genders and ... to the discussion of dealing with excess skin oil. “Oily skin is a challenge to ... can help remove the oily shine while keeping the skin fresh and clean,” says Dr. ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Calif. , March 27, 2017  Cryoport, Inc. ... that it intends to offer shares of common stock ... registration statement on file with the Securities and Exchange ... and other conditions, and there can be no assurance ... completed, or as to the actual size or terms ...
(Date:3/27/2017)... March 27, 2017  A new survey ... that Medicare,s Competitive Bidding Program (CBP) significantly reduced beneficiary ... The lack of choice forces beneficiaries to switch to ... health consequences. AADE,s survey is the ... and others pointing out the inherent problems with the ...
(Date:3/27/2017)... 2017 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus MD" ... MD is pleased to announce it has received conditional ... the TSX Venture Exchange.  Receiving the ... of significant achievements for Invictus-MD. Some of which include: ... AB Laboratories Inc. ("AB Labs"), a Licensed Producer under ...
Breaking Medicine Technology: